Countries where remdesivir is approved or supported for treating COVID-19

On Thursday, the US Food and Drug Administration approved remdesivir for treating patients hospitalized with COVID-19, making it the first and only drug approved for the disease.

A lab technicians holds the coronavirus disease (COVID-19) treatment drug "Remdesivir" at Eva Pharma Facility in Cairo, Egypt June 25, 2020. (photo credit: REUTERS/AMR ABDALLAH DALSH)
A lab technicians holds the coronavirus disease (COVID-19) treatment drug "Remdesivir" at Eva Pharma Facility in Cairo, Egypt June 25, 2020.
(photo credit: REUTERS/AMR ABDALLAH DALSH)
Gilead Sciences Inc's remdesivir is at the forefront in the fight against the novel coronavirus as one of the first drugs to have shown to be effective in countering COVID-19 in human trials.
On Thursday, the US Food and Drug Administration approved remdesivir for treating patients hospitalized with COVID-19, making it the first and only drug approved for the disease.
The following is a list of countries or regions that have approved, recommended or taken action in support of the antiviral drug for patients with the illness (in chronological order):    
    
United States  (Oct-22): FDA approves drug for treating patients hospitalized with COVID-19.    
                                                        
Japan  (May-07) Japan approved remdesivir for COVID-19 - the country's first officially authorized drug to tackle the disease. 
                                                              
United Kingdom (May-26): Agrees to provide remdesivir to certain COVID-19 patients.
                                                                   
South Korea (May-29; Jun-26): Approves remdesivir import; adds remdesivir to coronavirus treatment guidelines.   
                                               
Taiwan (May-30): Approves remdesivir in patients with severe COVID-19, says efficacy and safety of remdesivir have been supported by preliminary evidence.  
                                                                
India (Jun-01): Approves emergency use of remdesivir                        
            
Singapore (Jun-10): Approves remdesivir for severely ill COVID-19 patients.        
                                                           
Israel (Jun-16): Accepts Gilead's donation of remdesivir, to treat moderately and critically ill patients.                                
          
European Union (Jul-03): Gives conditional approval for the use of remdesivir in severe COVID-19 patients, making it the region's first therapy to be authorized to treat the virus.         
                                              
 Australia (Jul-10): Grants provisional approval to use remdesivir as a treatment option for adults and adolescent patients with severe COVID-19 symptoms and have been hospitalised.